A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

Launched by SHANGHAI CHEST HOSPITAL · May 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how to better monitor patients with stage III non-small cell lung cancer (NSCLC) that has specific genetic mutations. The researchers want to find out if testing for minimal residual disease (MRD)—which looks for tiny amounts of cancer that might still be in the body after treatment—can help predict if and when the cancer may return. By understanding MRD status, doctors hope to improve how they assess the risk of recurrence and manage patient care.

To participate in this trial, patients must be at least 18 years old and have been diagnosed with stage III NSCLC confirmed through imaging and biopsy. They should also have specific driver gene mutations and be willing to undergo surgery or radiation treatment. Participants will need to provide blood samples periodically and agree to work closely with the medical team for follow-ups. This trial is currently recruiting participants, and it offers a chance to contribute to important research that could lead to better outcomes for others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy
• • 2. Age≥ 18
• • 3. ECOG PS:0-1
• • 4. Tumor molecular testing by EBUS or biopsy confirmed positive for one or more of the following driver genes:EGFR\\ALK\\ROS1\\RET\\KRAS\\PIK3CA\\BRAF\\HER2\\MET
• • 5. Patients who met and agreed to surgery or radical chemoradiotherapy, and the remaining samples after cutting tissue sections did not affect the possible further clinical treatment of the subject
• • 6. Provide 20 mL peripheral blood samples periodically
• • 7. The subjects volunteered to join the study, and signed the informed consent form, with good compliance, and actively cooperated with the hospital for routine clinical diagnosis and treatment follow-up
• Exclusion Criteria:
• • 1. Patients with other malignancies within 5 years
• • 2. According to the investigator, the patient also had other diseases that may affect the follow-up and short-term survival
• • 3. The subject had other factors that may lead to the termination of the study, such as other serious diseases (including mental illness), serious laboratory abnormalities, and family or social factors that affected the safety of the subject, or the collection of data and samples

Trial Officials